International Journal of Biology, Pharmacy
and Allied Sciences (IJBPAS)
'A Bridge Between Laboratory and Reader'

www.ijbpas.com

CROSS SECTIONAL STUDY OF BIOCHEMICAL PARAMETERS DURING FIRST AND SECOND WAVE OF COVID 19 PATIENTS ADMITTED IN RURAL TERTIARY CARE HOSPITAL CHENGALPET DISTRICT

SANTHOSH V, WEIZMAN JJS[*] AND A. KHADEJA BI

Department of Biochemistry, Karpaga Vinayaga Institute of Medical Sciences and Research Centre, Chengalpet, Tamilnadu-603308

[*]**Corresponding Author: Dr. J.John Samuel Weizman: E Mail: johnsamuel.weizman07@gmail.com**

ABSTRACT

Introduction: The first case of COVID 19 emerged in city of Wuhan, China in December 2019, Till August 2020 World Health Organization (WHO) reported that 24.7 million cases were reported inclusive of 830,000 deaths. Many countries have suffered a two-wave pattern of COVID cases, called first wave and the second wave. This study was aimed to compare the levels of Biochemical markers (LDH, ferritin, D-dimer and CRP) from patients infected during the first wave and the second wave in a rural tertiary care hospital Chengalpet district. **Methodology**: A Cross sectional study was done between June to August 2020 and June to August 202. About 299 RT-PCR positive SARS COV-2 patients serum/plasma samples were collected from first and second wave of COVID-19 The inclusion criteria were individuals with age above 18years with RT-PCR positive for SARS COV-2 and the exclusion criteria was age below 18 years. **Result**: The median value of LDH for second wave is 611 and the first wave 473 which lies between the (425 – 804) and (385 - 625) as its 25th percentile and 75th percentile respectively, For ferritin, median value of second wave is 402 and the first wave is 254 which lies between the (217 - 707) and (112 - 422) at its 25th percentile and 75th percentile respectively, D-Dimer has its median value as 0.56 for second wave and 0.54 for first wave. CRP has its median value as 35 for second wave and 44 for first wave which lies between the (21 – 56) and (25 - 65) as its 25th percentile and 75th percentile respectively, Thus LDH, Ferritin and D-dimer serum levels are raised in second wave and CRP raised in First wave of COVID-19. **Conclusion**: The D-

dimer, CRP, LDH and ferritin were strongly associated with COVID-19 disease and these biomarkers have been shown to have the capacity to diagnose, predict severity and complication and have usefulness in monitoring treatment response

Keywords: COVID-19, LDH, Ferritin, D-dimer, CRP

INTRODUCTION

The first case of COVID 19 emerged in city of Wuhan, China in December 2019. Till August 2020 World Health Organization (WHO) reported that 24.7 million cases were reported inclusive of 830,000 deaths [1]. Many countries have suffered a two-wave pattern of COVID cases, called first wave and the second wave [2]. Outbreak of second wave of COVID-19 were reported in October 2020 by majority of countries with a significant rise in new cases recorded thus attaining their highest number of total cases [3, 4]. Japanese population suffered second wave of COVID-19 in late March and early May with sudden rise in new cases. With these outbreaks, the severity of the disease is still uncertainly projected. The clinical presentation of COVID-19 may vary from asymptomatic or mild symptoms to severe multi organ failure and even death. Symptoms get changed between first and second wave of COVID which includes fever, sore throat, loss of sense of smell and or taste, non-productive cough, shortness of breath, general fatigue, headache and myalgia. Some patients 15-20% may tend to develop acute respiratory distress syndrome (ARDS), kidney failure and heart failure [5-7]. COVID-19 had similar clinical and pathological findings with the Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) due to the genetic homologies between coronaviruses [8]. Severe form of COVID-19 cause a hyper inflammatory response, which leads to a pathological dysfunction of innate host defence mechanisms, causing complications like cytokine release syndrome (cytokine storm) and multiple organ failure [9]. Apart from circulating cytokines levels, there are certain inflammatory markers known to be associated with the severity of the disease such as lactate dehydrogenase (LDH), ferritin, D-dimer and C-reactive protein (CRP) [10]. Some of them are non-specific markers of sepsis and or inflammation while others are consistent with cytokine releasing syndrome (CRS). Thus been elevated with the severity of the disease [11]. The enzyme Lactate dehydrogenase (LDH) is involved in glycolysis which catalyses pyruvate to lactate conversion and present in all tissues. In viral infection LDH is released from cells upon damage of their cytoplasmic membrane [12]. Ferritin is a

storage protein of iron, it is one of the inflammatory marker. During infections due to virus or Bacteria, a decline in its transporting capacity resulting from spleen and liver damage increases ferritin. Levels also rise during infections due to iron release from the endoplasmic reticulum [13] D-dimers is one of the peptide fragments synthesized as a cross linked fibrin during degradation by plasmin. Its level gets increased in any process that involve breakdown of fibrin and production of fibrin, such as surgery, acute infections and acute or chronic inflammatory states [14]. C-reactive protein (CRP) is an acute-phase reactant protein. Liver synthesis CRP during inflammation, it has a plasma half-life of 19 hours [15]. This study was aimed to compare the levels of Biochemical markers (LDH, ferritin, D-dimer and CRP) from patients infected during the first wave and the second wave in rural tertiary care hospital Chengalpet district.

METHODOLOGY

A cross sectional study was conducted to compare the levels of biochemical parameters in admitted COVID 19 patients during the first and second wave of COVID-19 in rural tertiary care hospital in Chengalpet district. Time duration of first wave and second wave taken for this study is between May 2020 to August 2020 and May 2021 to August 2021 respectively. About 299 RT-PCR positive SARS COV-2

patients serum/plasma samples were collected from first and second wave of COVID-19. The inclusion criteria's were individuals with age above 18years with RT-PCR positive for SARS COV-2 and the exclusion criteria was age below 18 years.

The primary variables included in this study were lactate dehydrogenase (LDH), ferritin D-dimer, C-reactive protein (CRP). In this study, Lactate dehydrogenase (LDH) analysed in Pyruvate method (BA 200), C-reactive protein (CRP)and Ferritin were analysed in Nephelometric method (Mispa-i2 Agapee) and D-dimer was anlysed in ELFA method in first wave (Minividas) and Nephelometric method (Mispa-i2 Agapee) in the second wave. Biological reference interval for LDH: 207-414 U/L, Ferritin: 30-220 ng/ml, CRP:0-6mg/l and cut off for D-dimer: <0.5 microgram/ml. After collecting the reports of biochemical parameters, a cross sectional study comparing Biochemical parameters was done among the admitted patients during first and second waves of COVID-19 pandemic.

RESULTS

The median value of LDH for second wave is 611 and the first wave 473 which lies between the (425 – 804) and (385 - 625) as its 25th percentile and 75th percentile respectively. LDH is higher in second wave with wide interval than first wave comparatively. For ferritin, median value of

second wave is 402 and the first wave is 254 which lies between the (217 - 707) and (112 - 422) at its 25th percentile and 75th percentile respectively. Ferritin is higher in second wave with wide interval than first wave comparatively. D-Dimer has its median value as 0.56 for second wave and 0.54 for first wave. Median D-Dimer was found to be higher in second wave than in first wave. CRP has its median value as 35 for second wave and 44 for first wave which lies between the (21 – 56) and (25 - 65) as its 25th percentile and 75th percentile respectively. Median CRP for first wave is higher than second wave **(Table 1, Figure 1-4)**.

Table 1

| MEDIAN (INTER-QUARTILE RANGES)			
variables	**First wave**	**Variables**	**Second wave**
LDH (n = 299)	**473 (385 - 625)**	**LDH (n = 302)**	**611 (425 - 804)**
FERRITIN (n=299)	**254 (112 - 422)**	**FERRITIN (n=302)**	**402 (217 - 707)**
D-DIMER (n=298)	**0.54 (0.33 -0.72)**	**D-DIMER (n=295)**	**0.56 (0.28 - 1.26)**
CRP (n=299)	**44 (25 - 65)**	**CRP (n=301)**	**35 (21 - 56)**

Figure 1

Figure 2

Figure 3

Figure 4

DISCUSSION

COVID 19 has become one of the major global problem for the past few years and it is characterized with increased mortality, higher rate of complications and even it has created major impact on global economy. Thus there is a need for cost effective early diagnosis for the management of COVID-19. Various studies have found that there is an increased level of biochemical parameters in COVID-19 patients and also pro inflammatory cytokines were elevated in severe cases when compared to mild or moderate cases. In our study comparison of biochemical parameters (LDH, CRP, D-dimer and Ferritin)was done between first and second wave of COVID19. Our findings of CRP, LDH, ferritin and D-dimer levels shows significant raise in RT-PCR positive COVID-19 patients. A study in Italy stated that LDH and CRP are markedly rise in COVID-19 patients and this finds to be alternative for RT-PCR [16]. Further studies reported that LDH, ferritin, D-dimer and CRP were used to evaluate the severity of the disease and a high level are associated with mortality and poor outcome [17, 18]. Results of the various analysis have shown that LDH, ferritin D-dimer and CRP are associated with increased risk of COVID-19 infection. A recent study [19] revealed that high

levels of ferritin, D-dimer and CRP are associated with poor outcome in COVID-19. In every tissue LDH is present and is a cytoplasmic glycolytic enzyme. In general, increased levels of LDH indicate tissue damage and common in patients infected with MERS-CoV [20-22], H7N9 [23, 24] and H5N1 [25]. Study stated that LDH is an independent factor of mortality in patients with H1N1 infection [26] and severe acute respiratory syndrome [27-29]. Increased LDH in early phase of COVID-19 severe cases suggest that there is a possible subclinical tissue damage. The virus binds to ACE2(human angiotensin converting enzyme 2) receptor in the lung [30, 31], so the lungs are the first organ to get affected, but on disease progression, various cytokine abnormalities and multiple organs dysfunction can be seen in severe COVID 19 patients, resulting systemic organ damage due to excessive activation of immune system. Further LDH isoenzymes test can help to locate the damaged tissues or organs. Ferritin acts as a marker for serious illness, liver damage, and treatment course in COVID 19. From destroyed hepatocytes the acute phase protein Ferritin gets released [32, 33]. Impaired liver activity or a metabolic syndrome results in Ferritinemia [34]. Abnormal ferritin levels in Covid-19 patients have more risk of liver injury and severe illness and studies found that liver

injury is common in covid-19 patients. The early analysis of ferritin can efficiently have recognized catastrophic disease, liver damage and prognosis of covid-19 patients. The D-dimer is a degradation product of fibrin and is a small protein fragment formed by fibrinolysis. The identification of circulating D-dimer concentrations in blood is found to be a sensitive marker in diagnosing thrombotic states like pulmonary embolism and Disseminated intravascular coagulation [35]. Increased D-dimer levels in COVID-19 patients might be helpful to identify in patients with pulmonary complications, high disease severity and risk of venous thromboembolism. This would assist with risk stratification and the early introduction of therapeutic measures that might reduce COVID19 related morbidity and mortality. COVID-19 patients with elevated D-dimer levels may require hospitalization, despite the clinical presentation severity. CRP levels are in association with the level of inflammation, and its concentration level is not affected by age, sex and physical condition. CRP levels can activate the complementary pathway and enhance phagocytosis and clearing the pathogenic microorganisms invading the body. CRP levels found to be useful in the early phase of pneumonia diagnosis. It is an important biomarker for the evaluation and diagnosis of severe pulmonary infectious diseases. A

study shows increased value of CRP levels in severe pneumonia. CRP levels were also correlating with the lung lesions and disease severity. In the early phase of COVID-19, CRP levels found to be associated with lung lesions and disease severity and also to monitor the disease improvement. Thus, the Biomarkers D-dimer, CRP, LDH and ferritin is simple, convenient, cost effective and useful in predicting the severity and diagnosis of COVID-19 before proceeding to the high cost techniques like RT-PCR and CT imaging.

CONCLUSION

In this study on comparing the levels of Biochemical parameters between first and second wave of COVID-19 the LDH, ferritin and D-dimer raised in second wave and CRP raised in first wave of COVID-19, Thus the D-dimer, CRP, LDH and ferritin were strongly associated with COVID-19 disease and these biomarkers have been shown to have the capacity to diagnose, predict severity and complication and have usefulness in monitoring treatment response. This will help in early isolation and treatment and decreases the rate of morbidity and mortality in COVID-19.

REFERENCES

[1] Hong H, Wang Y, Chung HT, Chen CJ. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. Pediatric Neonatol. 2020 Apr; 61(2): 131-132.

[2] Chen YC, Cao Q, Chen CL, Chiu CH. Kawasaki disease and COVID-19: A pretext for a hot topic. J Formos Med Assoc. 2021 Jan 8: S0929-6646, (21)00003- 6

[3] Ali A, Bai J, Ma Z. Second wave of Covid-19; are more episodes down the road? BMJ. 2020;371.

[4] Bassino JP, Ladmiral G. Excess mortality during the first and second waves of COVID-19 spread in Japan (December 2019-May 2020); evidence from municipality level data. SSRN. 2020. [Preprint]. DOI:10.2139/ ssrn.3651968.

[5] Kluge S, Janssens U, Welte T, Carstens SW, Marx G, Karagiannidis C. Recommendations for critically ill patients with COVID-19. Med Klin Intensiv med Notfmed, 2020. 115(3): 175- 177.

[6] Zhonghua Liu Xing Bing Xue Za Zhi, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China 2020. 41(2): 145-151.

[7] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, *et al*. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 2020. 382(18): 1708-1720.

[8] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, *et al*. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020. 395(10223): 497-506.

[9] Potempa LA, Rajab IM, Hart PC, Bordon J, Botran RF. Insights into the Use of C-Reactive Protein as a Diagnostic Index of Disease Severity in COVID-19 Infections. Am J Trop Med Hyg. 2020, 103(2): 561-563.

[10] Black S, Kushner I, Samols D. C–reactive protein. J Biol Chem, 2004. 279(47): 48487-48490.

[11] Mackay AD, Marchant ED, Munk DJ, Watt EK, Hansen JM, Thomson DM, Hancock CR. Multitissue analysis of exercise and metformin on doxorubicin-induced iron dysregulation. Am J Physiol Endocrinol Metab. 2019, 316(5): E922-E930.

[12] Yousif NG, Altimimi AN, Al-amran FG, Adrienne J, Al-Fadhel SM, Hussien SR. *et al*. Hematological changes among Corona virus-19 patients: a longitudinal study. Sys Rev Pharm 2020; 11(5): 862-866.

[13] Thachil J, Lippi G, Favaloro EJ. D-Dimer Testing: Laboratory Aspects and Current Issues.

Methods Mol Biol. 2017; 1646: 91- 104. doi:

[14] Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, *et al*. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis. 2020 Jul 28; 71(15): 706-712.

[15] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, *et al*. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020. 395(10229): 1054-1062.

[16] Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med. 2020 Jun 25; 58(7): 1095-1099.

[17] Pan F, Yang L, Li Y, Liang B, Li L, Ye T, Li L, Liu D, Gui S, Hu Y, Zheng C. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci, 2020. 17

[18] Liu SL, Wang SY, Sun YF, Jia QY, Yang CL, Cai PJ, Li JY, Wang L, Chen Y. Expressions of SAA, CRP, and FERR in different

severities of COVID-19. European Review for Medical and Pharmacological Sciences, 01 Nov 2020, 24(21): 11386-11394.

[19] Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020 Jan-Dec; 14: 1753466620937175.

[20] Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752 –61.

[21] Alsolamy S. Middle East respiratory syndrome: knowledge to date. Crit Care Med. 2015;43(6):1283 –90.

[22] Al Ghamdi M, Alghamdi KM, Ghandoora Y, Alzahrani A, Salah F, Alsulami A, Bawayan MF, Vaidya D, Perl TM, Sood G. Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS

CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis. 2016;16(1):174.

[23] Shi J, Xie J, He Z, Hu Y, He Y, Huang Q, Leng B, He W, Sheng Y, Li F. A detailed epidemiological and clinical description of 6 human cases of avian-origin influenza A (H7N9) virus infection in Shanghai. PLoS One. 2013;8

[24] Mei Z, Lu S, Wu X, Shao L, Hui Y, Wang J, Li T, Zhang H, Wang X, Yang F. Avian influenza A (H7N9) virus infections, Shanghai, China. Emerg Infect Dis. 2013;19(7):1179.

[25] Oner AF, Bay A, Arslan S, Akdeniz H, Sahin HA, Cesur Y, Epcacan S, Yilmaz N, Deger I, Kizilyildiz B. Avian influenza A (H5N1) infection in eastern Turkey in 2006. New Engl J Med. 2006;355(21):2179 –85.

[26] Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, Lee PO, Ng TK, Ng WF, Lee KC. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med. 2003;139(9): 715 –23.

[27] Xi X, Xu Y, Jiang L, Li A, Duan J, Du B, Chinese CCCT. Hospitalized adult patients with 2009 influenza A (H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis. 2010;10(1):256.

[28] Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld AJ. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med. 2014;42(3):691 –700.

[29] Hoeboer SH, Oudemans-van Straaten HM, Groeneveld AJ. Albumin rather than C-reactive protein may be valuable in predicting and monitoring the severity and course of acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new onset fever. BMC Pulm Med. 2015;15(1):22.

[30] Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, Si H, Zhu Y, Li B, Huang C. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270 –3.

[31] Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260 –3.

[32] Milind Rane, Umesh Bhadade, Face and Palmprint Biometric Recognition by using Weighted Score Fusion Technique, IEEE Int. Conf. Inf. Process. PuneCon 2020.

[33] Milind Rane, Umesh Bhadade, Dual Palm print based Human Recognition using Fusion, Int. Conf. Innov. Inf. Commun. Technol. 2020 (Scopus Published).

[34] H. Xie, J. Zhao, N. Lian, S. Lin, Q. Xie, H. Zhuo, Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study, Liver Int. 40 (6) (2020) 1321–1326.

[35] Olson JD. D-dimer: an overview of hemostasis and fibrinolysis, assays, clinical applications. Adv Clin Chem. (2015) 69:1–46.